Onconase cytotoxic RNase enzyme data

ACEL (Bloomfield, N.J.) reported Phase I/II findings in 32 evaluable patients, eight of whom had at least a partial response, with one complete responder who has survived for more than 3.5 years.

At the meeting of the Society for Biological Therapy in Napa, Calif., the interim results of the 51-patient trial show a median survival of the eight patients who showed evidence of clinical activity as 2.2 years (1.6 years for the seven patients who responded with stabilization of their disease). Median survival for this cancer has been 7.5-12 months in other trials over the past two decades, the company said. Five patients have survived from 1.6 to 3.6 years. ...